From Dallas Express · Dallas Express · · 3m
Estradiol patch shortage hits pharmacies
Demand for menopause hormone therapy surged after FDA removed safety warnings, leaving women unable to fill prescriptions.
In brief
Demand for menopause hormone therapy surged after FDA removed safety warnings, leaving women unable to fill prescriptions. Estradiol patch shortages are real at pharmacy counters even though the FDA says supply has doubled, and women forced off treatment face rapid symptom return. Originally reported by Dallas Express.
FDA removes menopause warnings
In November 2025, the FDA stripped black box warnings about cardiovascular disease, breast cancer and dementia from hormone therapy labels, citing outdated 2002 research.
Demand for patches soars
Estrogen patch prescriptions jumped 162% over two years. A May survey found nearly half of women on hormone therapy were having trouble filling prescriptions.
Pharmacies can't keep up
While the FDA says supply nearly doubled and patches remain available, hospital pharmacists and patients report specific brands and doses missing for weeks.
“specific brands and doses missing for weeks”
FDA vs. real-world shortages
The FDA's shortage list is based on manufacturer reports and total supply. The American Society of Health-System Pharmacists list shows what hospitals actually cannot obtain.
How patches work
Estradiol patches deliver estrogen through skin to treat hot flashes, night sweats and bone loss. Applied once or twice weekly, they bypass the digestive tract.
Symptoms return quickly
The FDA warns not to stop patches without talking to a clinician. About 50% of women experience symptom return when hormone therapy stops.
“do not stop or change the medication without talking to a clinician”
What happens without patches
Women forced off treatment face hot flashes, night sweats, sleep disruption, mood changes and vaginal dryness. These are the original symptoms returning, not new side effects.
Switching brands isn't simple
Some patients can switch brands or doses, but insurance often covers one product and rejects another. Pharmacies don't stock every strength.
Twenty years of outdated warnings
A 2002 study halted the Women's Health Initiative trial, leading to 2003 FDA black box warnings. Prescriptions fell for two decades until the FDA reversed course in 2025.
Manufacturers caught unprepared
Six companies make estradiol patches in the US. Bayer expects temporary constraints on one Climara dose into early 2027. Manufacturers say they weren't staffed for the policy shift.
FDA expedites production
The FDA is reviewing manufacturer submissions, adding production shifts, expanding batch sizes and prioritizing estradiol patch manufacturing.
HHS pushes alternatives
Secretary Robert F. Kennedy Jr. met with manufacturers and pharmacy leaders in September 2026 to discuss supply challenges and teach doctors about alternative hormone products.
What women can do now
Ask pharmacists about substitute FDA-approved patches, call prescribers before stopping, check back for inventory, and report local shortages to the FDA.
In short
Estradiol patch shortages are real at pharmacy counters even though the FDA says supply has doubled, and women forced off treatment face rapid symptom return.
